Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 November 1993Website:
http://www.incyte.comNext earnings report:
13 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 13 min agoDividend
Analysts recommendations
Institutional Ownership
INCY Latest News
Incyte announced impressive revenue growth of 24% in the third quarter, largely due to Jakafi and Opzelura. The approval of new products, such as Niktimvo, is expected to help diversify Incyte's income and lessen its dependence on Jakafi. The earnings per share (EPS) shortfall is mainly due to high research and development costs, which are important to reassure investors about possible future revenue declines from Jakafi.
Incyte Corporation will hold a conference call on October 29, 2024, at 8:00 AM ET to discuss their Q3 2024 financial results. Key company participants include the CEO, CFO, and other executives, along with various analysts from major financial institutions. The call will be recorded for future reference.
Incyte has shared mixed results for the third quarter, with earnings falling short of expectations, but revenues exceeding them thanks to higher sales of Jakafi and Opzelura.
The main figures for Incyte (INCY) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to compare these important metrics with Wall Street's predictions and the results from the same period last year.
Incyte exceeded Wall Street's expectations for its third-quarter revenue and increased its annual sales prediction for its best-selling drug on Tuesday, thanks to strong patient demand.
Incyte (INCY) reported quarterly earnings of $1.07 per share, which is lower than the Zacks Consensus Estimate of $1.12 per share. This is also a decrease from the earnings of $1.10 per share from the same period last year.
On Tuesday, Incyte Corporation (INCY) announced its revenue for the third quarter, which reached $1.14 billion. This figure represents a 24% increase compared to the same period last year and exceeds the expected amount of $1.08 billion.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SCTopEmployers--Incyte has been recognized as one of the top five companies in Science Magazine's 2024 Top Employers List.
INCY's earnings for the third quarter of 2024 are expected to increase due to higher sales of Jakafi and Opzelura.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).
What type of business is Incyte?
Incyte Corporation is a biopharmaceutical company. The company offers the drug JAKAFI for the treatment of myelofibrosis and polycythemia, as well as Iclusig, a kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Its clinical products include ruxolitinib, a Phase III drug for steroid-refractory chronic graft-versus-host disease (GVHD); and Phase II drug for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company is developing itacitinib, which is in Phase III clinical trials for the treatment of naïve chronic GVHD; and pemigatinib, which is in Phase II clinical trials for the treatment of bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and tumor-agnostic syndrome. The company is also involved in the development of Parsaclisib, which is in Phase II clinical trials for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. The company is developing INCMGA0012, which is in Phase II clinical trials for high-grade endometrial MSI cancer, Merkel
What sector is Incyte in?
Incyte is in the Healthcare sector
What industry is Incyte in?
Incyte is in the Biotechnology industry
What country is Incyte from?
Incyte is headquartered in United States
When did Incyte go public?
Incyte initial public offering (IPO) was on 04 November 1993
What is Incyte website?
https://www.incyte.com
Is Incyte in the S&P 500?
Yes, Incyte is included in the S&P 500 index
Is Incyte in the NASDAQ 100?
No, Incyte is not included in the NASDAQ 100 index
Is Incyte in the Dow Jones?
No, Incyte is not included in the Dow Jones index
When was Incyte the previous earnings report?
No data
When does Incyte earnings report?
The next expected earnings date for Incyte is 13 February 2025